Demonstrates a novel multi-layer countermeasure against Andes Hantavirus, implying proactive prevention strategies.
We present a multi-layer host-directed and virus-directed countermeasure protocol for Andes Hantavirus, the only hantavirus known to transmit person-to-person. The architecture, termed the Receptor Shield, treats viral ingress as an unauthorized execution on a Biological Operating System. Three core layers are defined: (1) competitive inhibition via peptidomimetic decoys that saturate the viral Gc glycoprotein, (2) endothelial barrier reinforcement through S1P signaling stabilization, and (3) lethal mutagenesis via nucleoside analogs to force the viral polymerase into error catastrophe. A fourth immune-moderating layer is proposed to dampen the cytokine storm that drives pathogenesis. The approach is framed as a security stack rather than a collection of drugs, emphasizing proactive receptor encryption over reactive treatment. An experimental validation pathway (in silico, in vitro, ex vivo, in vivo) and safety pharmacology considerations are outlined.
No takes yet. Share an insight, caveat, or question.
Alexander Jorge Cisneros (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: